Download PDF
Hamostaseologie 2020; 40(02): 221-225
DOI: 10.1055/a-1150-2016
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Acquired von Willebrand Syndrome and Platelet Function Defects during Extracorporeal Life Support (Mechanical Circulatory Support)

Axel Schlagenhauf
1   Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2   Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
,
Johannes Kalbhenn
3   Department of Anesthesiology and Critical Care, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
,
Ulrich Geisen
4   Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Friedhelm Beyersdorf
5   Department of Cardiovascular Surgery, University Heart Center Freiburg – Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Barbara Zieger
1   Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
› Author Affiliations
Further Information

Publication History

12 December 2019

10 March 2020

Publication Date:
26 May 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Patients with ventricular assist devices (VADs) and extracorporeal membrane oxygenation (ECMO) suffer from an increased risk for thromboembolic events as well as for hemorrhages. High shear stress in the mechanical device results in acquired von Willebrand syndrome (AVWS), characterized by a loss of high-molecular-weight multimers of von Willebrand factor (VWF) leading to an increased bleeding risk. Onset of AVWS occurs within hours, persists during the whole period of mechanical support, and subsides rapidly after explantation. Patients with the older HeartMate II exhibit more severe AVWS than those with the newer HeartMate III, thanks to lower shear stress in the latter. All ECMO and VAD patients exhibit thrombocytopathia and often thrombocytopenia which further increases the bleeding risk. Etiological models for AVWS are increased cleavage by the metalloproteinase ADAMSTS13, mechanical destruction of VWF, and shear-induced VWF binding to platelets. Platelet secretion defects may be caused by transient platelet activation leading to degranulation. AVWS can be diagnosed by detection of VWF multimers using gel-electrophoresis and functional assays of varying sensitivity (VWF ristocetin cofactor activity, VWF activity, VWF collagen binding). Platelet dysfunction is monitored using light transmission aggregometry and secretion defects are detectable using flow cytometry. Modest use of anticoagulants and a target-controlled therapy based on VWF parameters and other coagulation and platelet parameters are shown to be beneficial in this patient group. Persistent hemorrhages may be controlled with tranexamic acid and platelet concentrates. Prompt weaning from the device, when indicated, is the best therapeutic option to prevent recurrent bleeding.

Keywords

ventricular assist devices - ECMO - acquired von Willebrand syndrome - platelet secretion
 

  • References

  • 1 Schramm R, Morshuis M, Schoenbrodt M. , et al. Current perspectives on mechanical circulatory support. Eur J Cardiothorac Surg 2019; 55 (Suppl. 01) i31-i37
    CrossrefPubMedGoogle Scholar
  • 2 Thiagarajan RR, Barbaro RP, Rycus PT. , et al; ELSO Member Centers. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J 2017; 63 (01) 60-67
    CrossrefPubMedGoogle Scholar
  • 3 Kirklin JK, Naftel DC, Pagani FD. , et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 2015; 34 (12) 1495-1504
    CrossrefPubMedGoogle Scholar
  • 4 Bourque K, Cotter C, Dague C. , et al. Design rationale and preclinical evaluation of the HeartMate 3 left ventricular assist system for hemocompatibility. ASAIO J 2016; 62 (04) 375-383
    CrossrefPubMedGoogle Scholar
  • 5 Mehra MR, Naka Y, Uriel N. , et al; MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med 2017; 376 (05) 440-450
    CrossrefPubMedGoogle Scholar
  • 6 Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J ThrombHaemost 2015; 13 (10) 1757-1767
    CrossrefPubMedGoogle Scholar
  • 7 Aubron C, DePuydt J, Belon F. , et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care 2016; 6 (01) 97
    CrossrefPubMedGoogle Scholar
  • 8 Klinzing S, Wenger U, Stretti F. , et al. Neurologic injury with severe adult respiratory distress syndrome in patients undergoing extracorporeal membrane oxygenation: a single-center retrospective analysis. AnesthAnalg 2017; 125 (05) 1544-1548
    PubMedGoogle Scholar
  • 9 Cavayas YA, Del Sorbo L, Fan E. Intracranial hemorrhage in adults on ECMO. Perfusion 2018; 33 (1, Suppl): 42-50
    CrossrefPubMedGoogle Scholar
  • 10 Harvey L, Holley CT, John R. Gastrointestinal bleed after left ventricular assist device implantation: incidence, management, and prevention. Ann Cardiothorac Surg 2014; 3 (05) 475-479
    PubMedGoogle Scholar
  • 11 Park SJ, Milano CA, Tatooles AJ. , et al; HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5 (02) 241-248
    CrossrefPubMedGoogle Scholar
  • 12 Demirozu ZT, Radovancevic R, Hochman LF. , et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011; 30 (08) 849-853
    PubMedGoogle Scholar
  • 13 Kim JH, Brophy DF, Shah KB. Continuous-flow left ventricular assist device-related gastrointestinal bleeding. Cardiol Clin 2018; 36 (04) 519-529
    PubMedGoogle Scholar
  • 14 Geisen U, Brehm K, Trummer G. , et al. Platelet secretion defects and acquired von Willebrand syndrome in patients with ventricular assist devices. J Am Heart Assoc 2018; 7 (02) e006519
    PubMedGoogle Scholar
  • 15 Panigada M, Artoni A, Passamonti SM. , et al. Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. Minerva Anestesiol 2016; 82 (02) 170-179
    PubMedGoogle Scholar
  • 16 Hellmann C, Schmutz A, Kalbhenn J. Bleeding during veno-venous ECMO cannot reliably be predicted by rotational thrombelastometry (ROTEM™). Perfusion 2018; 33 (04) 289-296
    CrossrefPubMedGoogle Scholar
  • 17 Benk C, Lorenz R, Beyersdorf F. , et al. Three-dimensional flow characteristics in ventricular assist devices: impact of valve design and operating conditions. J Thorac Cardiovasc Surg 2011; 142 (05) 1019-1026
    CrossrefPubMedGoogle Scholar
  • 18 Geisen U, Heilmann C, Beyersdorf F. , et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33 (04) 679-684
    CrossrefPubMedGoogle Scholar
  • 19 Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J AtherosclerThromb 2015; 22 (03) 265-271
    PubMedGoogle Scholar
  • 20 Tauber H, Ott H, Streif W. , et al. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers. Anesth Analg 2015; 120 (04) 730-736
    CrossrefPubMedGoogle Scholar
  • 21 Baldauf C, Schneppenheim R, Stacklies W. , et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J ThrombHaemost 2009; 7 (12) 2096-2105
    CrossrefPubMedGoogle Scholar
  • 22 Kalbhenn J, Schlagenhauf A, Rosenfelder S, Schmutz A, Zieger B. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: Rapid onset and fast recovery. J Heart Lung Transplant 2018; 37 (08) 985-991
    CrossrefPubMedGoogle Scholar
  • 23 Baghai M, Heilmann C, Beyersdorf F. , et al. Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices. Eur J Cardiothorac Surg 2015; 48 (03) 421-427
    CrossrefPubMedGoogle Scholar
  • 24 Lambert MP. Inherited platelet disorders: a modern approach to evaluation and treatment. Hematol Oncol Clin North Am 2019; 33 (03) 471-487
    CrossrefPubMedGoogle Scholar
  • 25 Rauch A, Legendre P, Christophe OD. , et al. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. ThrombHaemost 2014; 112 (05) 1014-1023
    PubMedGoogle Scholar
  • 26 Restle DJ, Zhang DM, Hung G. , et al. Preclinical models for translational investigations of left ventricular assist device-associated von Willebrand factor degradation. Artif Organs 2015; 39 (07) 569-575
    CrossrefPubMedGoogle Scholar
  • 27 Nascimbene A, Hilton T, Konkle BA, Moake JL, Frazier OH, Dong JF. von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support. J Heart Lung Transplant 2017; 36 (04) 477-479
    CrossrefPubMedGoogle Scholar
  • 28 Scheppke L, Murphy EA, Zarpellon A. , et al. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood 2012; 119 (09) 2149-2158
    CrossrefPubMedGoogle Scholar
  • 29 Vincent F, Rauch A, Loobuyck V. , et al. Arterial pulsatility and circulating von Willebrand factor in patients on mechanical circulatory support. J Am Coll Cardiol 2018; 71 (19) 2106-2118
    CrossrefPubMedGoogle Scholar
  • 30 Nascimbene A, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016; 127 (25) 3133-3141
    CrossrefPubMedGoogle Scholar
  • 31 Kawahito K, Mohara J, Misawa Y, Fuse K. Platelet damage caused by the centrifugal pump: in vitro evaluation by measuring the release of alpha-granule packing proteins. Artif Organs 1997; 21 (10) 1105-1109
    PubMedGoogle Scholar
  • 32 Lukito P, Wong A, Jing J. , et al. Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ibα and glycoprotein VI. J ThrombHaemost 2016; 14 (11) 2253-2260
    CrossrefPubMedGoogle Scholar
  • 33 Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. SeminThrombHemost 2002; 28 (02) 227-238
    PubMedGoogle Scholar
  • 34 Tiede A, Priesack J, Werwitzke S. , et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J ThrombHaemost 2008; 6 (04) 569-576
    CrossrefPubMedGoogle Scholar
  • 35 Geisen U, Zieger B, Nakamura L. , et al. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo. Thromb Res 2014; 134 (02) 246-250
    CrossrefPubMedGoogle Scholar
  • 36 Bansal A, Uriel N, Colombo PC. , et al. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. J Heart Lung Transplant 2019; 38 (08) 806-816
    CrossrefPubMedGoogle Scholar
  • 37 Geisen U, Beyersdorf F, Zieger B. Acquired von Willebrand syndrome and left ventricular assist devices. J Heart Lung Transplant 2020; 39 (01) 89
    PubMedGoogle Scholar
  • 38 Randi AM, Smith KE, Castaman G. von Willebrand factor regulation of blood vessel formation. Blood 2018; 132 (02) 132-140
    PubMedGoogle Scholar
  • 39 Patel SR, Madan S, Saeed O. , et al. Association of nasal mucosal vascular alterations, gastrointestinal arteriovenous malformations, and bleeding in patients with continuous-flow left ventricular assist devices. JACC Heart Fail 2016; 4 (12) 962-970
    CrossrefPubMedGoogle Scholar
  • 40 Lahav J, Jurk K, Hess O. , et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002; 100 (07) 2472-2478
    CrossrefPubMedGoogle Scholar
  • 41 Ang AL, Teo D, Lim CH, Leou KK, Tien SL, Koh MB. Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation -- a single centre experience. Vox Sang 2009; 96 (01) 34-43
    CrossrefPubMedGoogle Scholar
  • 42 Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. AnesthAnalg 2014; 118 (04) 731-743
    PubMedGoogle Scholar
  • 43 Krueger K, Schmutz A, Zieger B, Kalbhenn J. Venovenousextracorporeal membrane oxygenation with prophylactic subcutaneous anticoagulation only: an observational study in more than 60 patients. Artif Organs 2017; 41 (02) 186-192
    CrossrefPubMedGoogle Scholar
  • 44 Fischer Q, Huisse MG, Voiriot G. , et al. Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients?. Transfusion 2015; 55 (01) 51-54
    CrossrefPubMedGoogle Scholar
  • 45 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
    CrossrefPubMedGoogle Scholar
  • 46 Kalbhenn J, Wittau N, Schmutz A, Zieger B, Schmidt R. Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy. Perfusion 2015; 30 (08) 675-682
    CrossrefPubMedGoogle Scholar
  • 47 Morici N, Varrenti M, Brunelli D. , et al. Antithrombotic therapy in ventricular assist device (VAD) management: From ancient beliefs to updated evidence. A narrative review. Int J Cardiol Heart Vasc 2018; 20: 20-26
    PubMedGoogle Scholar